Multispecialty Trial Success: AGIBOT Laparoscopic Surgical Robot Completes 31 Complex Procedures with 100% Efficacy

On December 5, 2024, AGIBOT laparoscopic surgical robot developed by AGIBOT Medical Technology (Suzhou) Co., Ltd (AGIBOT) successfully completed the last case of robotic-assisted lung segmental resection at the First Affiliated Hospital of Zhengzhou University under the supervision of Professor Qi Yu. At this point, the multi-disciplinary and multi-centre clinical trial of AGIBOT Laparoscopic Surgical Robot has been completed.

This multi-specialty registered clinical trial of AGIBOT Laparoscopic Surgical Robot was led by Run Run Shaw Hospital affiliated to Zhejiang University School of Medicine, together with the First Affiliated Hospital of Zhengzhou University and the First Medical Centre of the General Hospital of the People’s Liberation Army, with the participation of several disciplines of General Surgery (including Hepatobiliary, Gastrointestinal, and Colorectal Specialties), Thoracic Surgery, and Gynaecology, and a series of medium- to high-level difficult surgeries were carried out. The trial aims to validate the effectiveness and safety of the AGIBOT Laparoscopic Surgical Robot in complex surgeries, providing innovative treatment options for both doctors and patients.

The clinical trial at the First Affiliated Hospital of Zhengzhou University was personally guided by Vice President Professor Guo Ruixia, and promoted by a team of experts including Professor Qi Yu, Professor Yuan Weitang, Professor Fu Yang, Professor Zhai Wenlong, and Professor Wang Qian, and a total of 31 multidisciplinary clinical surgeries were successfully completed. The types of surgeries include partial hepatectomy, radical gastric cancer, radical colorectal cancer, lobectomy/segmental lung resection, radical cervical cancer, and comprehensive staging of endometrial cancer, etc. The surgical process was smooth and stable, with a success rate of 100%, and intra-operative indexes and post-operative results suggesting that the surgical results are good.

In gynaecological surgery, a patient with preoperative pathology suggestive of plasma endometrial cancer was found to have extensive dense pelvic adhesions, which posed a considerable challenge to the operator and the robot. After completing the conventional total hysterectomy + bilateral adnexectomy + pelvic and para-abdominal lymph node dissection with the assistance of the robot, the surgeon also needed to perform the resection of the greater omentum, a step that required the surgical robot to perform a second docking. In this process, the AGIBOT Laparoscopic Surgical Robot demonstrated its advantages of agile deployment and flexible docking, which enabled the entire operation to be completed smoothly within 2.5 hours, effectively improving surgical efficiency.

Prof. Wang Qian from the Department of Gynaecology noted, “With its stable performance and accuracy, AGIBOT Laparoscopic Surgical Robot has performed well in clinical trials, bringing great benefits to patients while improving surgical efficiency, and we look forward to continuous optimization in the future to help complete more complex and difficult surgeries.”

Professor Qi Yu from the Department of Thoracic Surgery commented, “With its good flexibility and precision, AGIBOT Laparoscopic Surgical Robot has played an important role in lung anatomy surgery, which not only improves the precision and safety of anatomical lung segment surgery, but also helps patients to retain more lung tissue and function while ensuring a radical outcome.”

Professor Yuan Weitang of Colorectal and Anal Surgery remarked, “In colorectal surgery, AGIBOT Laparoscopic Surgical Robot is able to assist the lead surgeon to easily achieve fine excursion and level expansion, and even in the body of a patient with a narrow pelvis, it is able to achieve smooth and fine operation, which greatly improves the quality of surgery.”

Professor Zhai Wenlong of the Department of Hepatobiliary and Pancreatic Surgery noted, “The stability and precision of AGIBOT Laparoscopic Surgical Robot provides a strong guarantee for achieving precision in liver surgery, while enabling the safety of difficult surgeries to be significantly improved.”

Prior to the clinical trial, a team of experts, including Professor Qi Yu, Professor Yuan Weitang, Professor Fu Yang, Professor Zhai Wenlong, and Professor Wang Qian, collaborated with AGIBOT’s product and medical teams to conduct a series of animal tests to familiarize themselves with the operation of the equipment, as well as initially assessing the safety and efficacy of the product, laying a solid foundation to ensure the smooth conduct of the clinical trial.

During the trial, clinical researchers communicated with AGIBOT’s clinical support team, providing feedback on user needs from the clinical frontline, which greatly assisted in the iterative improvement of the product.

The successful conclusion of the multi-disciplinary and multi-centre clinical trial enrolment of AGIBOT Laparoscopic Surgical Robot further proves the clinical value of the AGIBOT Laparoscopic Surgical Robot and lays the foundation for its future clinical application. AGIBOT will continue to deepen the cooperation with clinical institutions, continue to improve the product performance, and jointly promote the popularity and universality of laparoscopic robotic surgery, so that it can be applied in a wider range of medical scenarios.